Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1

Status

Recruiting 2Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 5OTHER 3

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Breast 1

Conditions

Recurrence 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 610Carboplatin 375Paclitaxel 283Cisplatin 268Gemcitabine 256Pemetrexed 194Bevacizumab 191Nivolumab 190Docetaxel 190Injections 169Cyclophosphamide 148atezolizumab 138Capecitabine 134Fluorouracil 133Oxaliplatin 132Dexamethasone 129Fulvestrant 115durvalumab 114130-nm albumin-bound paclitaxel 111fludarabine 102Cetuximab 101Leucovorin 97Rituximab 96venetoclax 90Lenalidomide 84Prednisone 79enzalutamide 78Azacitidine 76Irinotecan 74Ipilimumab 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × 18-O-demethylcervinomycin A2 × 1 year × Clear all
NCT05351788 2026-05-12

SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 2 Recruiting
110 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05294172 2026-05-08

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 3 Active not recruiting
295 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT05445908 2026-05-08

SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 2 Active not recruiting
175 enrolled
Breast

Triple Negative Breast Neoplasms

NCT07296809 2026-05-08

SKB500 Combinations in Patients With Small Cell Lung Cancer

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 2 Recruiting
80 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT03848286 2026-05-05

KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 2 Completed
153 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡